B.C. Health Coalition urges province to end contract with U.S. owner of LifeLabs
Social Sharing
A public health advocacy group is urging the B.C. government to end its contract with the American company that owns LifeLabs, the province's main provider of outpatient lab services.
The B.C. Health Coalition has issued an open letter asking Premier David Eby to follow through on a directive he issued last week for all government bodies to review their connections to U.S. firms amid the tariff dispute, and cancel its contract with Quest Diagnostics.
The American firm acquired LifeLabs locations across Canada last year for $1.35 billion, and is now involved in a labour dispute with its B.C. workers, who are eight weeks into strike action.
The 1,200 striking workers, who are members of the B.C. General Employees' Union (BCGEU), have been conducting rotating job action, temporarily closing labs on certain days.
WATCH | Rotating strikes continue at LifeLabs in B.C.:
Rotating strikes continue at LifeLabs in B.C.
4 days ago
Duration 6:16
It's been over seven weeks since workers began job action against their employer LifeLabs, which provides diagnostic care under contract to the government. Union president Paul Finch said the company, whose ownership is based in America, should be reviewed as part of the B.C. government's directive to rip up contracts with U.S. companies.
The B.C. Health Coalition, which has about 800,000 members, says laboratory services should be fully brought into the public system. It says doing so would reduce wait times, save public money and improve both working conditions and patient care.
Coalition members and striking LifeLabs workers rallied outside the B.C. Legislature on Wednesday, calling on the province to take action.
"There is no economic justification to allow a U.S. corporation to provide outpatient diagnostic services in the province," BCGEU president Paul Finch said in a statement earlier this week. "Workers and the public are already noticing a decline in services since Quest took over last year."
A poll commissioned by the employees' union suggests 74 per cent of British Columbians oppose American companies running health services in the province.
In a statement to CBC News, the Ministry of Health said the province is currently in a 10-year contract with LifeLabs, which runs through March 2031.
"Cancelling the province's contract with LifeLabs right now would cause significant delays in basic lab testing and put patients at risk," the ministry said. "It would also cost hundreds of millions of dollars and take resources away from frontline services elsewhere."
While LifeLabs is now owned by Quest, the ministry noted it remains a Canadian-incorporated company. It is responsible for more than two-thirds of outpatient lab tests in B.C. — about 42 million, annually.
The province said it will ensure LifeLabs complies with all contract terms to maintain the quality, accessibility and cost of lab services.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
8 hours ago
- Cision Canada
Protecting Canada's livestock industry with a new vaccine bank Français
OTTAWA ON, /CNW/ - Canada is making significant progress towards the creation of a dedicated foot-and-mouth disease (FMD) vaccine bank, which will build on existing protections for the livestock industry and equip producers with another tool to control and eliminate the disease should an outbreak occur. Following a competitive procurement process, Public Services and Procurement Canada, on behalf of the Canadian Food Inspection Agency, awarded contracts to Boehringer Ingelheim Animal Health and Biogénesis Bagó SA to supply multiple types of vaccine products and develop Canada's first FMD vaccine bank. This FMD vaccine bank complements Canada's current access to vaccines through the North American Foot and Mouth Disease Vaccine Bank, ensuring readily available vaccines for Canadian producers. FMD is a highly contagious and severe disease that affects cattle, sheep, swine, and other cloven-hoofed animals. An FMD infection can cause painful blisters that make it hard for animals to eat, walk, and produce milk, leaving them weak and sick. Preparedness efforts, including building a Canadian FMD vaccine bank, are key to protecting Canadian animals and agriculture. Having a ready supply of FMD emergency vaccines will strengthen our ability to respond effectively to an outbreak should one occur. It could also reduce the number of cases and the duration of the outbreaks. Collaboration between Canada's federal, provincial and territorial governments along with stakeholders plays a key role in Canada's FMD prevention and preparedness plans. These efforts, combined with Canada's existing strict import requirements, on-farm biosecurity measures, and disease surveillance, continue to protect the health of Canadian animals and the economic prosperity of our producers and farming communities. Quotes "Today's announcement highlights our continued commitment to enhancing Canada's animal disease preparedness and prevention plans. Securing our own supply of FMD emergency vaccines will not only help reduce the spread during a potential outbreak but also help protect the livelihood of Canadian farmers by minimizing the impact on international trade." -Paul MacKinnon, President, Canadian Food Inspection Agency "Establishing a dedicated FMD vaccine bank is a vital tool in safeguarding the health of our livestock, market access and the future of our industry. CFIA's announcement marks a key milestone towards our shared goal of strengthening Canada's preparedness against the threat of foot-and-mouth disease. We will continue to work with governments and stakeholders to ensure Canada has a robust emergency preparedness and prevention strategy against FMD." -Tyler Fulton, President, Canadian Cattle Association "The FMD vaccine bank is an important investment in protecting Canadian livestock and livestock producers from this disease. The federal government's support is further proof the cooperative relationship between government and industry in Canada works for producers and processors from coast to coast. We look forward to continuing this partnership on other challenges together." - René Roy, Chair, Canadian Pork Council "Today's announcement is a welcome and pivotal step towards enhancing existing industry defenses, offering producers another critical tool to minimize the impact and return Canada back to 'FMD-free' status in the event of an outbreak. This is vital for protecting animal health and farm sustainability, contributing to a safe, reliable, and consistent food supply for Canadians." -David Wiens, President, Dairy Farmers of Canada Quick Facts Budget 2023 committed $57.5 million over five years, with $5.6 million ongoing, to the CFIA to establish an FMD vaccine bank for Canada, and to further develop FMD response plans. FMD is considered one of the greatest economic threats to Canadian animal agriculture and the economic impacts in Canada are estimated to between $22B and $75B (in 2025 CAD) depending on the mode of introduction and extent of spread. Canada has been free from FMD since 1952, and strict measures are in place to prevent the disease from entering Canada. FMD is not a public health risk and is not considered a food safety issue. Public Services and Procurement Canada led an open, fair and transparent competitive procurement process to establish the contract for the FMD vaccine bank. Information about the solicitation is available on CanadaBuys. Each day, hard-working CFIA employees—including inspectors, veterinarians and scientists—inspect food for safety risks, protect plants from pests and invasive species, and respond to animal diseases that could threaten Canada's national herd and human health. Guided by science-based decision-making and modern regulations, the Agency works tirelessly to ensure access to safe and healthy food in Canada, and support access to international markets for our high-quality agricultural products. To learn more, visit
Cision Canada
14 hours ago
- Cision Canada
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 Français
For over two decades, NOYCIA has fueled emerging research in Canada, driving scientific knowledge in cancer MONTREAL, June 10, 2025 /CNW/ - Novartis Canada is pleased to announce the winners of the 2025 Novartis Oncology Young Canadian Investigator Awards (NOYCIA), an annual national competition dedicated to advancing oncology through the promotion of research by supporting Canadian oncology researchers. This year marks the 22nd year of the awards, which took place on Sunday, June 1st at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. NOYCIA celebrates the innovative work by selecting ten oncology researchers from Canada who have had their abstracts accepted at ASCO and demonstrate excellence in their area of study. "At Novartis, we are deeply committed to advancing scientific knowledge through innovation and collaboration," said Sophia Kajla, Chief Scientific Officer and Vice-President, Scientific Affairs, Novartis Canada. "The NOYCIA Awards remain at the forefront of supporting innovative cancer research in Canada, reflecting Novartis Canada's ongoing commitment to advancing science and improving patient outcomes. We are proud to continue celebrating and investing in early-career oncology leaders who are pushing the boundaries of discovery and clinical impact." Following deliberation by NOYCIA's Scientific Panel, this year's award recipients were selected for their pioneering research, spanning a range of disciplines, from immune checkpoint inhibitors and immunotherapy to healthcare systems and health human resource planning: The 2025 NOYCIA recipients are: Immune Checkpoint Inhibitors and Immunotherapy: Luciana Siqueira, Princess Margaret Cancer Centre Abstract: The association between emotional distress prior to receiving immune checkpoint inhibitors and overall survival among patients with cancer: A population-based study Supervisors: Dr. Lawson Eng & Dr. Marcus Butler Edmond Rafie, Research Center of the Centre Hospitalier de l'Université de Montréal Abstract: Dietary compounds and patterns associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small cell lung cancer (NSCLC) Supervisor: Dr. Arielle Elkrief Patrick Tuan Hoang, University of Toronto Abstract: Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay Supervisor: Dr. Adrian Sacher Gregoire Marret, University Health Network Abstract: Spatial transcriptomics analysis to predict response to immune checkpoint blockade (ICB) in recurrent or metastatic head and neck squamous cell cancer (RM-HNSCC) Supervisor: Dr. Lilian Siu Rami Habib, McGill University Abstract: JAK inhibitor for the treatment of steroid refractory and life threatening immune-related adverse events secondary to immune checkpoint inhibitors Supervisor: Dr. Khashayar Esfahani Transcriptomics and Molecular Analysis: Xin Wang, Princess Margaret Cancer Centre Abstract: Correlative and spatial transcriptomic analysis of olaparib and durvalumab in patients with recurrent/refractory IDH-mutant gliomas Supervisor: Dr. Eric Chen Ronan McLaughlin, Princess Margaret Cancer Centre Abstract: NeoPancONE: GATA6 Expression as a Predictor of benefit to Peri-Operative Modified FOLFIRINOX in Resectable Pancreatic Adenocarcinoma (r-PDAC): A Multicentre Phase II study Supervisor: Dr. Jennifer Knox Patient Experience and Decision-Making: Rena Seeger, University of Ottawa Abstract: Exploring decisional needs of patients considering first line treatment of Advanced EGFR+ lung cancer: An interpretive descriptive study Supervisor: Dr. Paul Wheatley-Price Novel Therapeutic Approaches: Asli Munzur, University of British Columbia Abstract: Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: an exploratory post-hoc analysis of a randomized phase II trial (TheraP ANZUP 1603) Supervisor: Dr. Alex Wyatt Healthcare Systems and Workforce Planning: Philip Ding, University of Alberta Abstract: Rethinking future workforce planning by developing novel metrics of complexity in cancer care Supervisor: Dr. Winson Cheung "For over two decades, NOYCIA has been outstanding in encouraging and promoting Canadian-based cancer research, moving scientific knowledge and understanding in oncology forward through the endorsement of research," said Dr. Paul Wheatley-Price, NOYCIA Chair and medical oncologist, The Ottawa Hospital. "The calibre of research occurring in Canada is truly world-class, and the NOYCIA Awards provides the platform to recognize the tremendous contributions of our emerging leaders. It's incredibly rewarding to be part of this initiative and a privilege to continue to serve as the Chair of the Scientific Panel." In addition to recognizing the achievement and potential of scientific investigation, Dr. David Addiss, 2025 NOYCIA guest speaker and Director, Focus Area for Compassion and Ethics (FACE), Task Force for Global Health, encouraged the award recipients and other attendees to cultivate compassion, which is fundamental to the unique relationship between patients and their healthcare providers. "As clinicians and oncology researchers, you are motivated and sustained by compassion—the desire to alleviate and prevent suffering—which arises from a sense of shared humanity," said Dr. Addiss. "And although science shows that compassionate health care provides significant benefits for patients, providers and health systems, we face growing challenges of resource scarcity, time pressures, and other systemic constraints, which may limit our ability to fully realize this ideal in practice. Despite these challenges, connecting with and nurturing our compassionate impulse on a daily basis allows us to accompany and support our patients in a way that enhances both patient satisfaction and professional fulfillment." Mentorship Matters Program NOYCIA 2025 includes the Mentorship Matters Program which offers mentorship opportunities to trainees who attend the NOYCIA awards dinner. The program provides trainees with the opportunity to network with leaders in Canadian cancer centres. Canadian oncologists co-host a table during the NOYCIA awards allowing trainees from across Canada to have the opportunity to hear from mentors about career paths, programs and opportunities that their centres provide and to ask questions. About the Novartis Oncology Young Investigators Award (NOYCIA) With a mission to support Canadian oncology researchers, NOYCIA provides funding, support, and recognition to 10 researchers that demonstrate excellence in their specialist field of study. Eligible applicants include Post-Doctoral Students, Residents, Fellows, Graduate Students, Medical Students, PhD Candidates and Undergraduates who are affiliated with a Canadian institution and are the first author of an abstract accepted for the annual ASCO meeting. For more information about NOYCIA, go to: About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit
Toronto Sun
15 hours ago
- Toronto Sun
Families attend authorization hearings in Montreal for brainwashing class-action suit: 'It's destroyed a lot of lives':
The lawsuit covers alleged abuse at the Allan Memorial Institute between 1948 and 1964. Published Jun 09, 2025 • Last updated 15 hours ago • 3 minute read Lana Ponting, 83, says she was subjected to severe physical and mental abuse, along with psychiatric experimentation at the Allan Memorial Institute when she was only 15. Allen McInnis/Montreal Gazette Lana Ponting was only 15 years old when she was admitted to the Allan Memorial Institute in Montreal. As a rebellious teenager, it was believed the psychiatric hospital could address her 'stubbornness and disobedience.' This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Instead, she says, she was subjected to severe physical and mental abuse, along with psychiatric experimentation that would later become infamously known as the Montreal experiments. Now 83, frail and requiring a walker, Ponting travelled from Winnipeg to be at the Montreal courthouse Monday as authorization hearings in a class-action lawsuit over the alleged abuse began. 'It's destroyed a lot of lives,' Ponting said outside the courtroom, anger in her voice. '(I want them) to see us, to feel us. I'm alive. I will not stop. I will fight until the end.' Filed in 2019, the class-action request alleges the Canadian government funded psychiatric treatments by Dr. Donald Ewen Cameron at the institute between 1948 and 1964. The experiments were allegedly part of the CIA's MK-ULTRA program of covert mind-control. Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. In addition to the government, the lawsuit also targets McGill University, which was affiliated to the psychiatric hospital, and Montreal's Royal Victoria Hospital. 'This is not a medical or professional malpractice case. … This is a case of systemic abuse,' lawyer Jeff Orenstein told the court on Monday. 'When people went to the Allan Memorial, they were told they would be receiving legitimate treatment,' he added. 'Instead they were human guinea pigs.' The defendants are contesting the class-action request, partly arguing the families waited too long to file their claims according to the law. The Canadian government also contends that some families accepted $100,000 payments from the federal government in the 1990s, which then barred them from pursuing further legal action. They will plead their case on Tuesday. This advertisement has not loaded yet, but your article continues below. Orenstein, for his part, argues the victims were unable to act earlier because of the trauma and psychological pain they endured. He believes the suit could grow to include several hundred people. The lawsuit had tried to include the U.S. government as a defendant, but Quebec's Court of Appeal ruled that the U.S. cannot be sued in Canada for its alleged role in the experiments; the Supreme Court of Canada refused to review the case. Julie Tanny, the lead plaintiff in the case, said she spent years not speaking about what happened to her father, Charles, because of the stigma attached. The few times she did, she added, she was met with disbelief. Present for the hearing, Tanny said she still can't accept the way her father changed after his stay at the institute in 1957 to treat facial pain. This advertisement has not loaded yet, but your article continues below. She described the warm and engaged father she once knew as having completely 'evaporated' after his treatment. He grew distant and barely recognized his children. 'For a kid, it's very traumatizing to have that relationship go away and not really understand why,' said Tanny, 71. 'It was the beginning of a nightmare for hundreds and hundreds of families.' In court on Monday, Orenstein detailed the experiments Cameron carried out on patients, noting how they were all well-documented at the time. Rather than scientific efforts, he compared them to acts of psychological torture. He described how patients were allegedly subjected to sensory deprivation and drug-induced comas, forced to listen to repeated audio messages on loop and to undergo extensive electroshock treatment. This advertisement has not loaded yet, but your article continues below. In some cases, he said, people were reduced to a childlike state. Others left the hospital as 'robots with no human emotions.' Lisa Moore, whose mother Hélène was sent to the hospital in the early 1960s, left the courtroom in tears as the alleged abuse was described, her emotions too difficult to contain. Now 54, Moore grew up in foster care and spent decades resenting her mother for how she treated her. But hearing the extent of what she went through laid bare in court on Monday provided a new perspective. 'It wasn't her fault. They took away her ability for compassion,' said Moore, who reconciled with her mother in recent years. 'It's very overwhelming,' she added. 'I just keep imagining what it was like for her.' With files from The Canadian Press. Toronto Blue Jays Ontario Olympics Sunshine Girls Columnists
